Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
The U.S. FDA has issued a Warning Letter to Simtra BioPharma Solutions following cGMP deviations observed during an unannounced inspection at its Simtra Deutschland GmbH (formerly Baxter Oncology GmbH, FEI 3002806419) facility in Germany. The agency cited serious lapses in contamination control across aseptic processing lines, deficiencies in cleaning system piping, integrity testing, particle shedding, decontamination procedures, and validation of decontamination cycles. The site was inspected by FDA investigators Karen A Briggs, Justin A Boyd and Vivin George in September 2025
FDA cited repeated recoveries of gram negative organisms Sphingomonas, Methylobacterium, Bradyrhizobium, Ralstonia species, Cupriavidus species above acceptable levels in RABS, cleaning use points and during post production environmental monitoring. The long piping in the Cleaning system / CIP used to rinse critical interior surfaces, equipment surfaces and RABS lines had dead legs which can allow proliferation of microbial contamination. During investigation of past incidents, Firm itself had identified piping (cleaning system / CIP), equipment design, gaskets, maintenance in combination with residual moisture after cleaning as root causes for microbial contamination, yet corrective actions remained inadequate. Residual moisture in equipment and RABS after cleaning poses a significant risk to barrier system controls and interference with decontamination cycle efficacy and can lead to drug product contamination.
Simtra failed to maintain equipment and systems adequately in the aseptic processing lines and facility’s integrity testing program was found unreliable. The integrity testing program allowed repeated failures / repeat testing in the Pressure Decay Testing and when leak tests failed, repeat testing was often performed on a later date. This allowed batches to be manufactured on systems whose integrity has not been confirmed. For example, in one case, a failed integrity test was followed by a passing test only after 18 days—during which multiple batches were manufactured in the line. Also, the Quality Unit reviewed only transcribed data of integrity testing, not raw data.
FDA is concerned on the reliability of the integrity testing programme and on the Firms response to the Form 483 that wrong acceptance criteria were fed into the integrity testing device which caused many failures and the operators felt pressure decay failures are not indicative of non-integrity and they relied on visual inspection. FDA Warning letter asserts visual examinations cannot be substituted for integrity testing devices.
FDA observed fiber shedding and loose particles from materials used in aseptic areas (covers to protect end of sterile tubing, connections and other accessories). The Firms change control process was found lacking, as this new material was introduced without thorough evaluation after complaints about previously used material for particle generation. Firm’s response to the observation and retrospective review of batches for particulate contamination was inadequate as it was limited to the batches cited by FDA and fail to assess the characteristics of the particles.
Trend of routine recoveries of Biological Indicator (BI) growth at completion of validation cycles indicated that validation of decontamination cycles were inadequate. Acceptance criteria were inappropriate as it allowed routine recovery of multiple BI survivors – in all validation cycles positive recoveries upwards of 8 were identified yet only two cycles were considered unacceptable. Also location of BI placement is not specified or documented.
Investigation of validation failure investigation were also found inadequate. A validation failure was attributed to “rogue” phenomenon in a BI lot, but this fails to recognize the multiple positive BIs that occurred with other BI lots in the same year and the long-term trend of routine BI positives. FDA highlighted recurrent failures as indicative of poor cycle robustness and compromised sterility assurance in RABS environments.
The USFDA Form 483 issued to Simtra also observes other areas of cGMP violations – deficient investigation of foreign particles and complaints, OOS investigations, inadequate aseptic area environmental monitoring, lapses in cleaning and maintenance of equipment, document control issues, and even a crawling insect in a Grade D area. The 483 also flagged lack of authority of Quality control unit to review production records.
FDA directions to Simtra in Warning letter include:
The Simtra Form 483 and Warning Letter underscore the critical importance of robust design and validation of automated cleaning systems, well‑defined integrity testing program with immediate assessment of failures, effective systems and procedures for contamination control, validation of sterilisation of sterilisation processes and effective, validated decontamination programme in aseptic manufacturing facilities. Equally essential are comprehensive failure investigations that identify true root causes and drive meaningful CAPA implementation.
FDA findings also highlight the need for empowered Quality Unit oversight—with clear authority, adequate resources, and responsibility to monitor GMP operations, review production records, and enforce timely investigations of deviations and complaints. Strong management and quality systems, rigorous monitoring, and decisive corrective measures are fundamental to ensure the quality, safety, and integrity of products and processes.
Leave a Comment
You must be logged in to post a comment.